The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

Latest from The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James)

Oppong Sheds Light on Racial Disparities in Breast Cancer Diagnosis and Mortality

November 17, 2022

Dr Oppong discusses factors that contribute to the ongoing disparity in breast cancer deaths among Black women vs White women, the importance of increased access to high-quality screening, and the need for more inclusive research efforts to close the gaps in breast cancer diagnosis and care.

Stark Differences in Mortality Rates Emphasize Ongoing Racial Disparities in Breast Cancer

October 24, 2022

Bridget A. Oppong, MD, discussed the importance of recognizing and addressing gaps in outcomes between patients with breast cancer in different racial groups. She also addressed the need for better advocacy for Black patients and advocated for improved screening guidelines to close the gap in racial disparities in breast cancer care.

Long-Term Treatment With Ibrutinib Is Possible in Newly Diagnosed CLL/SLL

October 13, 2022

Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.

Combination Therapies and HER2-Targeted Agents Signal Favorable Responses in Gastrointestinal Cancers

August 12, 2022

Anne M. Noonan, MBBCh, discusses prominent new therapies in hepatocellular carcinoma, the benefits of immunotherapy in gastric cancer, chemotherapy developments in pancreatic cancer, and the importance of considering HER2-targeted therapy in metastatic colorectal cancer.

New Approvals Help Fill Unmet Need in Treating Chronic GVHD

July 26, 2022

A panel of hematology experts discuss use of steroids in the first-line setting as well as several subsequent-line treatments that have recently received FDA approval for patients with steroid-refractory chronic GVHD, which affects up to 50% of patients.

Pembrolizumab Monotherapy Adds Option in MSI-H/dMMR Endometrial Cancer

May 18, 2022

The FDA has approved pembrolizumab in patients with advanced endometrial cancer that is microsatellite instability-high or mismatch repair–deficient and who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

Ohio State Recruits Top Oncologist to Expand Cell Therapy Program, Lead Bone Marrow Transplant Services

March 22, 2022

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has recruited Marcos J. de Lima, MD, to lead its Blood and Marrow Transplant and Cellular Therapy programs, two key leadership positions within central Ohio’s only National Cancer Institute-designated comprehensive cancer center and largest freestanding hospital.